Mode
Text Size
Log in / Sign up
Phase 4 Completed N=152 Randomized Treatment

The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease

GERD Gastroesophageal Reflux Disease
Source: ClinicalTrials.gov NCT02505945 ↗
Enrolled (actual)
152
Serious AEs
0.7%
Results posted
Dec 2018
Primary outcomePrimary: Elimination of Moderate-severe Regurgitation at 6 Months — 10; 42 Participants
◆ Published Evidence
Highly cited
108citations · ~15 / year
Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: a randomized controlled trial.
Gastrointestinal endoscopy · 2019 · Likely link

Summary

This study compares mechanical sphincter augmentation (LINX Reflux Management System) to double-dose proton pump inhibitors (PPIs) for the management of reflux symptoms related to gastroesophageal reflux disease (GERD).

Linked Publications (3)

  • Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: a randomized controlled trial.
    Gastrointestinal endoscopy · 2019 · 108 citations · Likely link
  • Magnetic Sphincter Augmentation Superior to Proton Pump Inhibitors for Regurgitation in a 1-Year Randomized Trial.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020 · 64 citations · Open access · Likely link
  • Number of reflux episodes on pH-impedance monitoring associates with improved symptom outcome and treatment satisfaction in gastro-oesophageal reflux disease (GERD) patients with regurgitation.
    Gut · 2021 · 48 citations · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Elimination of Moderate-severe Regurgitation at 6 Months
10; 42
SECONDARY
Percentage of Subjects With ≥50% Reduction in Total Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) Scores
7; 38

Eligibility Criteria

Key Inclusion Criteria

  • Patient seeks consultation for lack of satisfactory symptom response to once daily PPIs.
  • Age≥ 21 years old.
  • Abnormal distal esophageal pH determined by total % time pH 3cm as determined by endoscopy.
  • Distal esophageal motility (average of sensors 3 and 4) is less than 35 mmHg peristaltic amplitude on wet swallows or 35.
  • Diagnosed with an esophageal motility disorder LES.
  • Esophageal stricture or gross esophageal anatomic abnormalities
  • History of/or known Barrett's esophagus.
  • Suspected or known allergies to titanium, stainless steel, nickel or ferrous materials.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02505945) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search